Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

Ultragenyx Pharmaceutical Inc. (RARE): $47.03

0.03 (+0.06%)

POWR Rating

Component Grades













Add RARE to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where RARE ranks best; there it ranks ahead of 69.37% of US stocks.
  • RARE's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • RARE ranks lowest in Momentum; there it ranks in the 21st percentile.

RARE Stock Summary

  • Of note is the ratio of ULTRAGENYX PHARMACEUTICAL INC's sales and general administrative expense to its total operating expenses; only 14.79% of US stocks have a lower such ratio.
  • For RARE, its debt to operating expenses ratio is greater than that reported by just 10.3% of US equities we're observing.
  • With a price/sales ratio of 9.85, ULTRAGENYX PHARMACEUTICAL INC has a higher such ratio than 88.01% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to ULTRAGENYX PHARMACEUTICAL INC, a group of peers worth examining would be MRKR, EDIT, FDMT, CYCN, and LVTX.
  • RARE's SEC filings can be seen here. And to visit ULTRAGENYX PHARMACEUTICAL INC's official web site, go to www.ultragenyx.com.

RARE Valuation Summary

  • RARE's price/earnings ratio is -6.7; this is 131.16% lower than that of the median Healthcare stock.
  • Over the past 104 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

Stock Date P/S P/B P/E EV/EBIT
RARE 2022-09-01 10.2 5.0 -6.7 -6.5
RARE 2022-08-31 10.0 4.9 -6.6 -6.4
RARE 2022-08-30 10.3 5.1 -6.8 -6.6
RARE 2022-08-29 10.3 5.1 -6.8 -6.6
RARE 2022-08-26 10.4 5.1 -6.9 -6.6
RARE 2022-08-25 10.8 5.3 -7.1 -6.9

RARE Growth Metrics

    The 4 year price growth rate now stands at 3.19%.
  • Its 2 year price growth rate is now at -8.84%.
  • Its 2 year cash and equivalents growth rate is now at -48.36%.
RARE's revenue has moved up $249,932,000 over the prior 33 months.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 334.314 -308.771 -505.938
2022-03-31 331.946 -296.87 -470.204
2021-12-31 351.406 -338.695 -454.025
2021-09-30 359.559 -346.803 -355.578
2021-06-30 359.382 -349.121 -351.425
2021-03-31 334.116 -196.414 -203.682

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
  • RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
  • ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.234 0.955 -0.414
2021-03-31 0.225 0.956 -0.267
2020-12-31 0.194 0.977 -0.277
2020-09-30 0.174 0.973 -0.420
2020-06-30 0.140 0.962 -0.540
2020-03-30 0.116 0.959 -0.769

RARE Price Target

For more insight on analysts targets of RARE, see our RARE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $143.67 Average Broker Recommendation 1.58 (Moderate Buy)

RARE Stock Price Chart Interactive Chart >

Price chart for RARE

RARE Price/Volume Stats

Current price $47.03 52-week high $104.31
Prev. close $47.00 52-week low $45.20
Day low $46.80 Volume 227,571
Day high $48.20 Avg. volume 560,051
50-day MA $54.06 Dividend yield N/A
200-day MA $64.87 Market Cap 3.29B

Ultragenyx Pharmaceutical Inc. (RARE) Company Bio

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company was founded in 2010 and is based in Novato, California.

RARE Latest News Stream

Event/Time News Detail
Loading, please wait...

RARE Latest Social Stream

Loading social stream, please wait...

View Full RARE Social Stream

Latest RARE News From Around the Web

Below are the latest news stories about ULTRAGENYX PHARMACEUTICAL INC that investors may wish to consider to help them evaluate RARE as an investment opportunity.

Ultragenyx to Participate at Citi BioPharma Conference

NOVATO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi's 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET. The live and archived webcast of the presentation w

Yahoo | September 1, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purchase an aggregate of 19,020 shares of common stock of the company and 12,910 restricted stock units of the company’s common stock to two newly hired non-executive officers of the company. The awards were approv

Yahoo | August 17, 2022

Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

Yahoo | July 29, 2022

Ultragenyx Pharma Posts Smaller Than Expected Q2 Loss, Reaffirms Guidance

Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Q2 sales reached $89.3 million, up from $86.97 million a year ago, beating the consensus of $87.51 million. The company recognized $64.0 million in Crysvita (burosumab) revenue in the Ultragenyx territories, including $51.6 million in collaboration revenue in the North American profit share territory and net product sales in other territories regions of $12.4 million. Yoyalty revenue related to European Crysvita sales was $5.4 million. Dojolvi's (tr

Yahoo | July 29, 2022

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 28, 2022

Read More 'RARE' Stories Here

RARE Price Returns

1-mo -8.45%
3-mo -5.71%
6-mo -28.10%
1-year -54.03%
3-year 10.27%
5-year -5.86%
YTD -44.07%
2021 -39.25%
2020 224.12%
2019 -1.77%
2018 -6.25%
2017 -34.03%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5975 seconds.